Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Aptose Bioscns (APTO)

Aptose Bioscns (APTO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Deciphera (DCPH) Rises 90% in the Past 6 Months: Here's Why

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.

BPMC : 45.85 (+0.39%)
APTO : 0.7300 (-2.60%)
DCPH : 16.58 (-0.78%)
ORIC : 5.60 (-0.88%)
Horizon (HZNP) Completes Enrollment in Phase IV TED Study

Horizon (HZNP) completes enrollment in the phase IV study evaluating Tepezza for the treatment of thyroid eye disease in patients with a low clinical activity score.

HZNP : 109.80 (-0.41%)
ATRA : 5.46 (+1.11%)
APTO : 0.7300 (-2.60%)
ORIC : 5.60 (-0.88%)
Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis

The FDA approves Sanofi (SNY) and its partner Regeneron's Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.

REGN : 769.94 (-1.40%)
SNY : 46.97 (+2.42%)
ATRA : 5.46 (+1.11%)
APTO : 0.7300 (-2.60%)
Merck's (MRK) Keytruda Gets Four New Approvals in Japan

The Ministry of Health, Labour and Welfare approves Merck's (MRK) anti-PD-1 therapy, Keytruda, for four new cancer indications in Japan.

MRK : 105.68 (+1.59%)
ATRA : 5.46 (+1.11%)
APTO : 0.7300 (-2.60%)
ORIC : 5.60 (-0.88%)
Seagen (SGEN) Inks Deal With LAVA Therapeutics for LAVA-1223

Seagen (SGEN) signs an exclusive agreement with LAVA Therapeutics to develop and commercialize the latter's preclinical asset, LAVA-1223, targeting EGFR-expressing solid tumors.

RHHBY : 38.7900 (+1.15%)
SGEN : 137.44 (+1.06%)
APTO : 0.7300 (-2.60%)
LVTX : 3.89 (+0.78%)
Emergent (EBS) Acquires Worldwide Rights to Smallpox Antiviral

Emergent (EBS) completes the acquisition of worldwide rights to Tembexa, an FDA-approved smallpox oral antiviral for all ages, from Chimerix.

EBS : 14.10 (+2.99%)
CMRX : 1.8200 (-0.55%)
ATRA : 5.46 (+1.11%)
APTO : 0.7300 (-2.60%)
Evaxion (EVAX) Enrolls First Patient in Phase IIb Melanoma Study

Evaxion (EVAX) enrolls the first patient in the phase IIb study evaluating its cancer therapy, EVX-01 in combination with Keytruda, for treating melanoma.

MRK : 105.68 (+1.59%)
APTO : 0.7300 (-2.60%)
ORIC : 5.60 (-0.88%)
EVAX : 1.7800 (-1.11%)
Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod

The European Commission approves Alnylam's (ALNY) Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.

ALNY : 220.95 (-1.42%)
ATRA : 5.46 (+1.11%)
APTO : 0.7300 (-2.60%)
ORIC : 5.60 (-0.88%)
Pacira (PCRX) Gets Positive CHMP View on Exparel Label Expansion

The CHMP gives a positive opinion on Pacira's (PCRX) marketed drug Exparel and recommended a marketing authorization for the product to treat postsurgical pain in children aged six years or older.

PCRX : 41.60 (+0.87%)
ATRA : 5.46 (+1.11%)
APTO : 0.7300 (-2.60%)
ORIC : 5.60 (-0.88%)
Seagen's (SGEN) Tukysa Gets FDA Priority Review for New Indication

FDA grants priority review to Seagen's (SGEN) sNDA for Tukysa in combination with trastuzumab for previously treated HER2-positive metastatic colorectal cancer. A decision is due on Jan 19, 2023.

RHHBY : 38.7900 (+1.15%)
SGEN : 137.44 (+1.06%)
APTO : 0.7300 (-2.60%)
ORIC : 5.60 (-0.88%)

Barchart Exclusives

10-Year Treasury Notes: Higher or Lower Rates to Come?
With the March Treasury futures, First Notice Day (FND), arriving on the last day of February, a significant seasonal pattern may impact the current uptrend. Add the explosive employment number, and the interest rate market is ripe for a correction. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar